Trial reportBritish journal of cancer2008
Phase II trial of imatinib mesylate in patients with metastatic melanoma.
Trial report in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00027586 (Phase II Trial of Gleevec), which is not on this map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.
- Interventions for melanoma in situ, including lentigo maligna.The Cochrane database of systematic reviews · 2014Pooled it
- Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.Cell reports. Medicine · 2024Trial
- Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.Pigment cell & melanoma research · 2014Trial
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.Investigational new drugs · 2012Trial
- Trial
- Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2009Trial
- Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance.Cancer biology & medicine · 2025Review
- Review
- Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches.Clinical & experimental metastasis · 2024Review
- Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.American journal of clinical dermatology · 2024Review
- Review
- Head and Neck Mucosal Melanoma: Where Are We Now?Current oncology reports · 2024Review
- Mechanically activated ion channel Piezo1 contributes to melanoma malignant progression through AKT/mTOR signaling.Cancer biology & therapy · 2022Article
- Article
- Melanoma Targeted Therapies beyondCancers · 2021Review
- Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment.American journal of clinical dermatology · 2021Review
- Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021Review
- RTK Inhibitors in Melanoma: From Bench to Bedside.Cancers · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 1 country.
Funding
Abstract
Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients whose tumours expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated with 400 mg of imatinib twice daily. One patient with metastatic acral lentiginous melanoma, containing the highest c-kit expression among all patients, had dramatic improvement on positron emission tomographic scan at 6 weeks and had a partial response lasting 12.8 months. The responder had a substantial increase in tumour and endothelial cell apoptosis at 2 weeks of treatment. Imatinib was fairly well tolerated: no patient required treatment discontinuation because of toxicity. Fatigue and oedema were the only grade 3 or 4 toxicities that occurred in more than 10% of the patients. Imatinib at the studied dose had minimal clinical efficacy as a single-agent therapy for metastatic melanoma. However, based on the characteristics of the responding tumour in our study, clinical activity of imatinib, specifically in patients with melanoma with certain c-kit aberrations, should be examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.